Compare Oxford Lane Capital Corp (OXLC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Tango Therapeutics Inc. — how do they compare? Oxford Lane Capital Corp trades at $8.22 (market cap $817.57M), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 4.6× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.78% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 51 Days and Tango Therapeutics Inc. for 0 Days on average.
| OXLC | TNGX | |
|---|---|---|
Market Cap | $817.57M | $3.75B |
Volume | 2,300,089 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $16.02 | $32.90 |
52-Week Low | $8.15 | $7.50 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $1.21B | $2.77B |
Dividend Yield | 28.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.34, down 3.02% on the day, with a bearish technical outlook and weak earnings performance. Recent quarters show significant EPS misses, including a -$6.23 actual versus $2.26 expected in Q1 2026. The company maintains a high dividend payout of $0.20 monthly, but negative ROE and ROA highlight profitability challenges. Net asset value updates indicate substantial unrealized losses, with revenue turning negative in 2026.
The outlook is cautious due to deteriorating fundamentals and high payout ratios exceeding sustainable levels. Investment opportunities exist for yield-seeking investors attracted to the deep discount to NAV, but risks include persistent earnings volatility, reliance on financing for cash flow, and competitive pressures in the CLO space. Analyst sentiment is mixed, with 50% buy ratings offset by bearish technical signals.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
